Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triheptanoin in Early Stage Huntington Disease
NCT01882062Phase 2Completed
- Sponsor
- Inserm
- Start
- May 2013
- Primary completion
- Jul 2013
- Modality
- SLNs, Nanostructured Lipid Carriers, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of triheptanoin in Huntington disease (HD), sponsored by Inserm. Primary endpoint: Ratio of Inorganic Phosphate (Pi) Over Phosphocreatine (PCr) at 1 month. Started May 2013; status: completed.
02
Drugs
triheptanoin
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NCT01882062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01882062.